Trial Profile
A phase III study to assess the efficacy of ZD6474 (ZACTIMA) plus best supportive care versus best supportive care in patients with locally advanced or metastatic (stage IIIB-IV) non-small cell lung cancer after therapy with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ZEPHYR
- Sponsors AstraZeneca
- 09 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2014 Planned End Date changed from 1 Sep 2012 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 22 Jun 2012 Planned end date changed from 1 May 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.